Nutrition & Biosciences

DUPONT™

Pharma Solutions

ETHOCEL™ Ethylcellulose

A Technical Review

A Portfolio of Versatile Solutions to Help Address a Variety of Formulation and Processing Needs

ETHOCEL™ Premium Polymers are essentially tasteless, colorless, odorless, non-caloric and very inert physiologically. DuPont, offers twelve different ETHOCEL™ Polymers for pharmaceutical applications. These include a variety of molecular weights, which translate into a range of viscosities in addition to various particle sizes for different application needs.

Comparison of ETHOCEL™ Grades

ETHOCEL™ Standard Grade	4 Premium	7 Premium	7 FP Premium	10 Premium	10 FP Premium	20 Premium	45 Premium	100 Premium	100 FP Premium	HP
Viscosity (mPa.s)	3 - 5.5	6 - 8	6 - 8	9 - 11	9 - 11	18 - 22	41 - 49	90 - 110	90 - 110	9 - 11
Ethoxyl Content (% wt)	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5	48 - 49.5
Loss on Drying (% wt)	2 Max	2 Max	2 Max	2 Max	2 Max	2 Max	2 Max	2 Max	2 Max	2 Max
Particle Size (microns)	N / A	N / A	140 Max, 5 - 15 Mean	N / A	100 Max, 3 - 15 Mean	N / A	N / A	N / A	150 Max, 30 - 60 Mean	D10 < 3, mean < 8, D90 < 15
Solvent Solubility	Ethanol, Acetone, Isopropanol, Methanol, and Combinations of All									

By selecting among these variables, it is possible for ETHOCEL™ to be used in a variety of pharmaceutical functions including: barrier coatings for modified / controlled release, granulation and direct compression aides, and taste masking.



Barrier Coating for Modified/Controlled Release

ETHOCEL™ Polymers have a long history in film and bead coating for controlled release applications. ETHOCEL™ forms a strong film with good adhesion. These polymers can offer a versatile diffusion barrier whose properties can be modified by film thickness (weight gain), level of water soluble pore-forming additives (such as METHOCEL™), plasticizer choice, solvent(s) used, or the viscosity (molecular weight) of ETHOCEL™.

This investigation explored different dissolution rates of multiparticulate beads which have been coated with ETHOCEL™ to form barrier membranes. Variables that significantly impact properties of coatings made with ETHOCEL™ include the molecular weight, solvent system, additives, and the amount of ETHOCEL™ applied.

In all experiments, barrier coatings were applied to non-pareils (30 – 35 mesh) which had been coated with Diphenhydramine HCl using a mini-fluid bed coater. Tri-ethyl citrate (TEC) and dibutyl sebacate (DBS) were the plasticizers used while hydroxypropyl methyl cellulose (HPMC) was used as the pore-former. ETHOCEL™ Std. 4, 7, 10, 20, 45, and 100 Premium were used to determine the influence of molecular weight on drug release rate. Lastly, a comparison of 7% weight gain vs. 13% weight gain was used to determine the influence of film thickness.



In Figure 1, ETHOCEL™ Std. 10 Premium was combined with either 1 or 3% TEC or DBS to measure the effect of plasticizer choice or combined with 1% HPMC to measure how water soluble pore-former additives influence drug release rates. As illustrated by Figure 1, all dissolution profiles were similar for plasticizer choice or pore-former additive. Pore-formers are commonly used in barrier coatings of multiparticulates since pure films made with ETHOCEL™ demonstrate drug dissolution rates too slow for pharmaceutical needs. In this experiment only a 1% addition of HPMC was used, a larger percentage of the total formulation could significantly increase drug dissolution rate.

Dissolution results are for Diphenhydramine HCl coated on nonpareil seeds followed by 13% weight gain coating of ETHOCEL™ Std. 10 Premium with either TEC, DBS, or HPMC.

Figure 1: Influence of Plasticizer Choice or Pore-Former [1]



(1)The properties shown are typical but not to be construed as specifications, data is based on results from internal studies

In Figure 2, ETHOCEL™ Std. 4, 7, 10, 45, and 100 Premium were used to coat the Diphenhydramine HCl coated non-pareils to a 13% weight gain. Dissolution rates decreased as a function of increasing viscosity grade. Viscosity grades are determined by the molecular weight of the ethylcellulose polymer chain. A higher molecular weight film is going to form a greater number of entanglements resulting in a film with fewer defects and reduced free volume causing drug transport to decrease through the polymer layer. Another way to decrease drug release rates is by increasing film thickness (weight gain).

Figure 3 demonstrates ETHOCEL™ Std. 10 Premium at 13% weight gain has a slower drug release rate than ETHOCEL™ Std. 10 Premium at 7% weight gain. For slowing drug release rate, it is generally more efficient to increase weight gain of ETHOCEL™ than to increase viscosity grade use in a coating solution. Barrier coatings made with ETHOCEL™ from organic solutions are also stable over time. Stability is a critical component to the pharmaceutical industry since final product performance must remain consistent even at longer shelf storage times. Figure 4 shows 0, 1, 3, and 6 month stability profiles of non-pareils with Diphenhydramine HCL coated with ETHOCEL™ Std. 10 Premium and DBS. Samples were either left in ambient conditions or placed in accelerated storage conditions (40°C & 75% relative humidity). In both accelerated and ambient conditions, the performance of barrier membranes made with ETHOCEL™ remained stable.

Figure 2: Influence of Molecular Weight on Dissolution Rates[1]



Dissolution results are for Diphenhydramine HCl coated on non-pareil seeds followed by 13% weight gain coating of ETHOCEL™ Std 4, 7, 10, 20, 45, or 100 Premium with DBS.

Figure 3: Influence of Film Thickness on Dissolution Rates[1]



Dissolution results are for Diphenhydramine HCl coated on non-pareil seeds followed by either 7% or 13% weight gain coating of ETHOCEL™ Std. 10 Premium with DBS..

Figure 4: Influence of Storage Conditions[1]



Dissolution results are for Diphenhydramine HCl coated on non-pareil seeds followed by 7% weight gain coating of ETHOCEL™ Std 10 Premium with DBS. Samples were taken at 0, 1, 3, and 6 months at ambient (amb) and accelerated (acc) conditions.

(1)The properties shown are typical but not to be construed as specifications,data is based on results from internal studies

The following conclusions were drawn:

- Plasticizer selection between TEC and DBS at these levels did not make a significant difference; however, the use of plasticizer is critical to apply a flexible, relaxed barrier coating to give consistent performance results
- Increasing the viscosity grade (molecular weight) of ETHOCEL™ used at the same weight gain will give decreased drug release rate
- ETHOCEL™ barrier coatings from organic solutions will give stable performance results in accelerated and ambient storage conditions

Direct Compression For Matrix Tablets

This investigation involved the use of ETHOCEL™ in a dry system by directly compressing unmilled and milled ETHOCEL TM Polymer into tablets. These tablets form a matrix from which the drug can be released over time. Typically using ETHOCEL™ involves dissolving the ethylcellulose polymer in an organic solvent and applying the solution to a substrate. However, this investigation is a completely different method of controlled drug release using ethylcellulose polymers because it does not use the polymer in the dissolved state.

Drug dissolution and tablet physical testing were completed on milled and unmilled ETHOCEL™ Std 7 Premium samples. ETHOCEL™ Std. 7 Prem. (unmilled – 313 µm), ETHOCEL™ Std. 7 Prem. (milled - 12.8 µm), and ETHOCEL™ Std. 7 Prem. (milled - 4.8 µm) will be used as sample identifier, where 313, 12.8 and 4.8 µm refer to the median particle size.

The tablet formulation used throughout the study was limited to the following ETHOCEL™ and drug ratio (Diphenhydramine HCL): 25% ETHOCEL™: 75% drug, 50% ETHOCEL™: 50% drug, and 75% ETHOCEL™ : 25% drug. 300 mg tablets were formed using a Carver (model C) laboratory press equipped with 13/32 in flat- faced-bevel-edged tolling using a compression force of 8,000 lb and a dwell time of 5 sec.

Table 1 shows the effects of milling and increased ethylcellulose content on tablet crushing strength. Tablet crushing strength values for tablets using a 25% level ETHOCEL™ Std. 7 Prem (unmilled – 313 µm) ranged from 7 to 13 kN. ETHOCEL™ Std. 7 Prem. (unmilled – 313 µm) and EC Std 7. Prem. (milled – 12.8 µm) had similar crushing strength values even with the large difference in their median particle sizes. Tablets using ETHOCEL™ Std 7. Prem (unmilled 4.8 µm) had the highest value at 13 kN. Tablets manufactured with 75% ETHOCEL™ Std. 7 Prem. (unmilled – 313 µm) had crushing strength values of 18 to 22 kN. Increasing polymer weight content had a significant impact on the strength of the tablets.

Table 1: Results of Tablet Physical Testing

Sample ETHOCEL™ Std. 7 Prem.: Drug Ratio	**Tablet Crushing Strength (kN, sd)**
ETHOCEL™ Std 7 Prem. (unmilled)	
25%: 75%	7.8, 0.94
75% : 25%	22.0, 0.59
ETHOCEL™ Std 7 Prem. (milled – 12.8 µm)	
25%: 75%	7.6, 1.59
75% : 25%	22.2, 1.36
ETHOCEL™ Std 7 Prem. (milled – 4.8 µm)	
25%: 75%	13.3, 1.53
75% : 25%	17.9, 1.32

The following conclusions were drawn:

- Polymer particle size had a significant effect on drug release times. The finely ground (milled) ETHOCEL™ samples extended the release of the model drug compound several times longer than the unmilled ETHOCEL™ samples
- Polymer viscosity grade (molecular weight) had a minor effect on drug release because the ethylcellulose was not in a hydrated state during drug dissolution
- Tablet crushing strengths were higher in tablets containing finely ground ETHOCEL™ than those containing unmilled ETHOCEL™.

Figures 5 – 8 show drug release from tablets containing unmilled and milled ETHOCEL™ Std. 7 Premium at concentrations of 25% (Figure 6), 50% (Figure 5), and 75% (Figure 7). It was observed that as polymer particle size decreased, drug release decreased (Figure 5 – 7); furthermore, as polymer concentration increased drug release decreased (Figure 8).

A secondary study utilizing the same methods was completed with milled and unmilled ETHOCEL™ Std. 100 Premium. This study demonstrated the same trends in respect to polymer concentration and particle size. However, when comparing ETHOCEL™ Std 7 Prem. to ETHOCEL™ Std. 100 Prem. polymer viscosity had little effect on drug release times.

Figure 5: Drug Dissolution from Tablets Containing ETHOCEL™ (1)



Std. 7 Prem. at 50% and Diphenydramine HCl at 50%

Figure 6: Drug Dissolution from Tablets Containing ETHOCEL™ (1)



Std. 7 Prem. at 25% and Diphenydramine HCl at 75%



(1)The properties shown are typical but not to be construed as specifications,data is based on results from internal studies

Figure 7: Drug Dissolution from Tablets Containing ETHOCEL™ (1)



Std. 7 Prem. at 75% and Diphenydramine HCI at 25%

Figure 8: Drug Dissolution from Tablets Containing ETHOCEL™ (1)



Std. 7 Prem. and Diphenydramine HCI



Nutrition & Biosciences
pharma.dupont.com

PB111-1

The information contained herein is based on data known to DuPont or its affiliates at the time of preparation of the information and believed by them to be reliable. This is business-to-business information intended for food, beverage and supplement producers, and is not intended for the final consumer of a finished food, beverage or supplement product. The information is provided "as is" and its use is at the recipient's sole discretion and risk. It is the recipient's sole responsibility to determine the suitability and legality of its proposed use of DuPont products for its specific purposes. Information and statements herein shall not be construed as licenses to practice, or recommendations to infringe, any patents or other intellectual property rights of DuPont or others.

DUPONT HEREBY EXPRESSLY DISCLAIMS (I) ANY AND ALL LIABILITY IN CONNECTION WITH SUCH INFORMATION, INCLUDING, BUT NOT LIMITED TO, ANY LIABILITY RELATING TO THE ACCURACY, COMPLETENESS, OR USEFULNESS OF SUCH INFORMATION, AND (II) ANY AND ALL REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO SUCH INFORMATION, OR ANY PART THEREOF, INCLUDING ALL REPRESENTATIONS AND WARRANTIES OF TITLE, NONINFRINGEMENT OF COPYRIGHT OR PATENT RIGHTS OF OTHERS, MERCHANTABILITY, FITNESS OR SUITABILITY FOR ANY PURPOSE, AND WARRANTIES ARISING BY LAW, STATUTE, USAGE OF TRADE OR COURSE OF DEALING.